07:48 AM EDT, 09/23/2025 (MT Newswires) -- Seres Therapeutics ( MCRB ) said Tuesday it is cutting its workforce by 25% as part of cost-cutting measures.

The biotech company said it will pay about $1 million to $1.4 million related to the cutbacks, mainly due to severance costs, which it said will be paid in Q4.

Seres added that it is retaining personnel who are critical to its preparation of a planned phase 2 study of SER-155 to treat bloodstream infections among certain patients.

The company said it has received "constructive feedback" regarding the phase 2 study from the US Food and Drug Administration, and that it expects approval of the trial. The primary endpoint of the trial includes a planned interim analysis to evaluate efficacy and futility.